122 related articles for article (PubMed ID: 36089788)
1.
Xu M; Wen J; Xu Q; Li H; Lin B; Bhandari A; Qu J
Curr Cancer Drug Targets; 2024; 24(2):220-229. PubMed ID: 36089788
[TBL] [Abstract][Full Text] [Related]
2. [Study on the Role and Mechanism of METTL3 Mediating the Up-regulation of
m6A Modified Long Non-coding RNA THAP7-AS1 in Promoting the Occurrence of
Lung Cancer].
Zhang Y; Wang Y; Liu M
Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):919-933. PubMed ID: 38163978
[TBL] [Abstract][Full Text] [Related]
3.
Zhou X; Lin L; Qi Y; Xu M; Xu Q; Wang Y; Qu J
Dis Markers; 2022; 2022():2562595. PubMed ID: 35968508
[TBL] [Abstract][Full Text] [Related]
4. Silencing of AHNAK2 restricts thyroid carcinoma progression by inhibiting the Wnt/β-catenin pathway.
Lin QY; Qi QL; Hou S; Chen Z; Jiang N; Zhang L; Lin CH
Neoplasma; 2021 Sep; 68(5):1063-1071. PubMed ID: 34374294
[TBL] [Abstract][Full Text] [Related]
5. LAGE3 promotes cell metastasis and stemness in non-small cell lung cancer companied with AKT/PI3K signaling pathway activation.
Zhang H; Jian J; Chen H; Zhu X; Xie J; Xu X
Pathol Res Pract; 2023 Aug; 248():154700. PubMed ID: 37473499
[TBL] [Abstract][Full Text] [Related]
6. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
[TBL] [Abstract][Full Text] [Related]
7. AHNAK Nucleoprotein 2 Performs a Promoting Role in the Proliferation and Migration of Uveal Melanoma Cells.
Li M; Liu Y; Meng Y; Zhu Y
Cancer Biother Radiopharm; 2019 Dec; 34(10):626-633. PubMed ID: 31621397
[TBL] [Abstract][Full Text] [Related]
8. AHNAK2 promotes thyroid carcinoma progression by activating the NF-κB pathway.
Ye R; Liu D; Guan H; AiErken N; Fang Z; Shi Y; Zhang Y; Wang S
Life Sci; 2021 Dec; 286():120032. PubMed ID: 34627772
[TBL] [Abstract][Full Text] [Related]
9. Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer.
Wang Y; Jin Y; Bhandari A; Yao Z; Yang F; Pan Y; Zheng Z; Lv S; Wang O
Onco Targets Ther; 2018; 11():37-46. PubMed ID: 29317832
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatics analysis of the clinical value and potential mechanisms of AHNAK2 in papillary thyroid carcinoma.
Xie Z; Lun Y; Li X; He Y; Wu S; Wang S; Sun J; He Y; Zhang J
Aging (Albany NY); 2020 Sep; 12(18):18163-18180. PubMed ID: 32966238
[TBL] [Abstract][Full Text] [Related]
11. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
[TBL] [Abstract][Full Text] [Related]
12. LEM domain containing 1 promotes thyroid cancer cell proliferation and migration by activating the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
Xu M; Lin B; Zheng D; Wen J; Hu W; Li C; Zhang X; Zhang X; Qu J
Oncol Lett; 2021 Jun; 21(6):442. PubMed ID: 33868480
[TBL] [Abstract][Full Text] [Related]
13. TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway.
Xu J; Li Z; Su Q; Zhao J; Ma J
Oncol Rep; 2017 Mar; 37(3):1555-1564. PubMed ID: 28098872
[TBL] [Abstract][Full Text] [Related]
14. Original tumour suppressor gene polycystic kidney and hepatic disease 1-like 1 is associated with thyroid cancer cell progression.
Zheng C; Quan R; Xia EJ; Bhandari A; Zhang X
Oncol Lett; 2019 Sep; 18(3):3227-3235. PubMed ID: 31452800
[TBL] [Abstract][Full Text] [Related]
15. Scavenger receptor class A, member 5 is associated with thyroid cancer cell lines progression via epithelial-mesenchymal transition.
Zheng C; Xia EJ; Quan RD; Bhandari A; Wang OC; Hao RT
Cell Biochem Funct; 2020 Mar; 38(2):158-166. PubMed ID: 31989658
[TBL] [Abstract][Full Text] [Related]
16. AHNAK2 Promotes the Progression of Pancreatic Ductal Adenocarcinoma by Maintaining the Stability of c-MET.
Chen Z; Miao P; Lin H; Lu Y
Cancer Manag Res; 2024; 16():431-444. PubMed ID: 38751848
[TBL] [Abstract][Full Text] [Related]
17. CITED1 gene promotes proliferation, migration and invasion in papillary thyroid cancer.
Xia E; Wang Y; Bhandari A; Niu J; Yang F; Yao Z; Wang O
Oncol Lett; 2018 Jul; 16(1):105-112. PubMed ID: 29928391
[TBL] [Abstract][Full Text] [Related]
18. AHNAK2 is a novel prognostic marker and correlates with immune infiltration in papillary thyroid cancer: Evidence from integrated analysis.
Zheng L; Li S; Zheng X; Guo R; Qu W
Int Immunopharmacol; 2021 Jan; 90():107185. PubMed ID: 33218938
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1.
Li X; Li H; Shao MM; Miao J; Fu Y; Hu B
Thorac Cancer; 2023 Aug; 14(22):2093-2104. PubMed ID: 37349884
[TBL] [Abstract][Full Text] [Related]
20. Down-Regulation of AHNAK2 Inhibits Cell Proliferation, Migration and Invasion Through Inactivating the MAPK Pathway in Lung Adenocarcinoma.
Wang DW; Zheng HZ; Cha N; Zhang XJ; Zheng M; Chen MM; Tian LX
Technol Cancer Res Treat; 2020; 19():1533033820957006. PubMed ID: 33000678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
